Axis Direct has released its October 2026 'Prime Research Services' report, offering a fresh assessment on key equities. The brokerage issued a BUY rating for Dr. Lal Pathlabs, citing strong B2C brand strength and superior capital efficiency. Conversely, the firm issued SELL ratings for Ambuja Cement and Suzlon, flagging significant margin pressure, rising operational complexities, and concerns over the profitability of capacity expansion programs. Investors should note these diverging views on growth versus operational leverage.
Axis Direct October 2026 Strategy Update: Dr. Lal Pathlabs, Ambuja, Suzlon
Dr. Lal Pathlabs receives a BUY rating; Ambuja Cement and Suzlon receive SELL ratings.
Reader Takeaway: Dr. Lal Pathlabs shows strong asset-light growth, while Ambuja and Suzlon face margin and execution headwinds.
What just happened
Axis Direct has updated its equity coverage under its 'Prime Research Services' framework for October 2026. The firm evaluates stocks using a dual-strategy approach, categorizing investments into 'High Growth & QARP' and 'Value or Contra' baskets. Each selection undergoes a rigorous ten-point forensic hygiene check covering balance sheet health, promoter pledging, and capital allocation efficiency.
Why this matters
The broker’s latest update highlights a strategic divergence in the market. Dr. Lal Pathlabs is favored for its strong B2C presence, which accounts for 74% of its revenue, and a healthy balance sheet characterized by zero net debt and Rs 1,332 crore in liquid reserves. In contrast, Ambuja Cement and Suzlon are flagged for margin compression and rising costs. For Ambuja, EBITDA margins contracted by 540 basis points to 13.8%, while Suzlon’s EBITDA remained flat despite a 26% growth in revenue, signaling a disconnect between top-line expansion and operational efficiency.
Risks to watch
For Ambuja Cement, the primary risk remains the integration of recently acquired assets, specifically Penna and Sanghi, which are operating at roughly 50% utilization. Suzlon faces risks from increasing execution complexity in its EPC projects, which are expected to constitute 50% of its order book by FY28, putting pressure on working capital and core business profitability.
Context metrics
Dr. Lal Pathlabs maintains an ROCE of 43.6% (excluding cash). Ambuja Cement reported Q2FY27 consolidated revenue of Rs 9,197 crore with an EBITDA per tonne drop to Rs 770. Suzlon reported Q2FY27 revenue of Rs 4,869 crore, though segment profit saw a decline of 22.5%.
What to track next
Investors should monitor the management's progress on Ambuja’s Rs 14,500 crore capex program and Suzlon's ability to manage its working capital requirements amidst a shifting order book composition.